Longboard pharmaceuticals: LinkedIn
“We are thrilled to announce topline data from our PACIFIC Study, evaluating bexicaserin (LP352), a potentially best-in-class and highly selective, oral, novel 5-HT2C receptor superagonist for seizures associated with a broad range of Developmental and Epileptic Encephalopathies (DEEs).
Click here for more detail. https://bit.ly/48uucKw“
